

Form PTO-1449 U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

Serial No.

02-030-A

10/366,191

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**



Applicant : Radka et al.

Filing Date:
February 12, 2003

Group: Not yet
assigned

U.S. PATENT APPLICATION DOCUMENTS

Examiner Initial	No.	Document Number	Filing Date	Name	Publication Date if Appropriate
/DB/	* 1.	09/800,594	3/6/01	Usman et al.	
	* 2.	10/201394	7/22/02	Vargeese et al.	
	* 3.	08/878,640	3/6/01	Ludwig et al.	
	* 4.	09/476,387	12/30/99	Beigelman et al.	
	* 5.	09/918,728	7/31/01	Beigelman et al.	
	* 6.	08/878,640	3/6/01	Ludwig et al.	
	7.	10/727,780	12/03/03	Vaish et al.	
	8.	60/543,480	02/10/04	Jadhav et al.	
	9.	20040037780		Parsons et al.	02/26/04
	10.	20010007666		Hoffman et al.	07/12/01
	11.	10/201,394	08/13/01	Vargeese et al.	
	12.	10/151,116	05/17/02	Matulic-Adamic	
/DB/	13.	10/665,951	09/18/03	McSwiggen et al.	

U.S. PATENT DOCUMENTS

Examiner Initial	No.	Document Number	Date	Name	Class	Subclass	Filing Date
/DB/	* 14.	4,987,071	1/22/91	Cech et al.			
	* 15.	5,028,524	7/2/91	Fujisawa et al.			
	* 16.	5,395,938	3/7/95	Ramakrishnan			
	* 17.	5,589,332	12/31/96	Shih et al.			
	* 18.	5,672,695	9/30/97	Eckstein et al.			
	* 19.	5,741,679	4/21/98	George et al.			
	* 20.	5,767,263	6/16/98	Usman et al.			
	* 21.	5,807,718	9/15/98	Joyce et al.			
	* 22.	5,834,186	11/10/98	George et al.			
	* 23.	5,849,902	12/15/98	Arrow et al.			
	* 24.	5,871,914	2/16/99	Nathan et al.			
/DB/	* 25.	5,989,912	11/23/99	Arrow et al.			

Examiner /David Blanchard/

Date Considered 07/03/2007

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with any communication.

Form PTO-1449 U.S. Department of Commerce
Patent and Trademark Office

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Atty. Docket No.

02-030-A

Serial No.

10/366,191

Applicant : Radka et al.

Filing Date:
February 12, 2003

Group: Not yet
assigned

Examiner Initial	No.	Document Number	Date	Name	Class	Subclass	Filing Date
/DB/	*26.	5,998,203	12/7/99	Matulic-Adamic			
	*27.	6,001,311	12/14/99	Brennnan			
	*28.	6,087,188	7/11/00	Johansen et al.			
	*29.	6,127,173	10/3/00	Eckstein et al.			
	*30.	6,159,714	12/12/00	Usman et al.			
	*31.	6,342,221	1/29/02	Thorpe et al.			
	32.	5,670,633	09/23/97	Cook et al.			
	33.	5,792,847	08/11/98	Buhr et al.			
	34.	5,898,031	04/27/99	Crooke			
	35.	6,005,087	12/21/99	Cook et al.			
	*36.	6,159,714	12/12/00	Usman et al.			
	37.	6,107,094	08/22/00	Crooke			
	38.	6,476,205	11/05/02	Buhr et al.			
	39.	6,140,491	12/31/00	Usman et al.			
	40.	6,395,713	05/28/02	Beigelman et al.			
	41.	6,447,796	09/10/02	Vook et al.			
	42.	6,180,613	01/30/01	Kaplitt et al.			
	43.	4,501,729	02/26/85	Boucher et al.			
	44.	6,592,904	07/15/03	Platz et al.			
↓	45.	6,582,728	06/24/03	Platz et al.			
	46.	6,565,885	05/20/03	Tarara et al.			
/DB/	47.	6,235,310	05/22/01	Wang et al.			

FOREIGN PATENT DOCUMENTS

Examiner Initial	No.	Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
/DB/	* 48.	WO 00/24931	5/4/00	PCT				
↓	* 49.	WO 00/26226	5/11/00	PCT				
↓	* 50.	WO 93/23569	11/25/93	PCT				
/DB/	* 51.	WO 96/10390	4/11/96	PCT				

Examiner /David Blanchard/

Date Considered 07/03/2007

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with any communication.

Form PTO-1449 U.S. Department of Commerce
Patent and Trademark Office

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Atty. Docket No.

02-030-A

Serial No.

10/366,191

Applicant : Radka et al.

Filing Date:
February 12, 2003Group: Not yet
assigned

Examiner Initial	No.	Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
/DB/	*	52.	WO 96/10391	4/11/96	PCT			
	*	53.	WO 96/10392	4/11/96	PCT			
	*	54.	WO 97/26270	7/24/97	PCT			
	*	55.	WO 98/27104	6/25/98	PCT			
	*	56.	WO 98/58058	12/23/98	PCT			
	*	57.	WO 99/29842	6/17/99	PCT			
	*	58.	WO 99/54459	10/28/99	PCT			
	*	59.	WO 99/55857	11/4/99	PCT			
CXXX- 2544		60.	99/53050	10/21/99	WO (Waterhouse et al.)			
CXXVII- 2435		61.	99/49029	09/30/99	WO (Graham et al.)			
CXXX- 2540		62.	00/63364	10/26/00	WO (Pachuk et al.)			
CXXII- 2332		63.	99/32619	07/01/99	WO (Fire et al.)			
CXLI-2825		64.	99/61631	12/02/99	WO (Heifetz et al.)			
XII-244		65.	89/02439	09/20/88	WO (Arnold et al)			
LVI-387		66.	95/06731	03/09/95	WO (Usman et al)			
LXIII-619		67.	95/11910	05/04/95	WO (Dudycz et al)			
CXXV- 2397		68.	00/44895	08/03/00	WO (Kreutzer et al)			
CXXI- 2330		69.	01/36646	05/25/01	WO (Zernicka- Goetz)			
CXXI- /DB/		70.	00/01846	01/13/00	WO (Plaetinck)			

Examiner /David Blanchard/

Date Considered 07/03/2007

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with any communication.

Form PTO-1449 U.S. Department of Commerce Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Atty. Docket No.	Serial No.
	02-030-A	10/366,191
	Applicant : Radka et al.	
	Filing Date: February 12, 2003	Group: Not yet assigned

Examiner Initial	No.	Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
2327 /DB/								
CXXII- 2333	71.	01/29058	04/26/01	WO (Mello and Fire)				
CXXI- 2328	72.	99/07409	02/18/99	WO (Deschamps- Depaillette)				
CXXII- 2334	73.	00/44914	08/03/00	WO (Li et al)				
XIV-281	74.	94/02595	07/02/93	WO (Sullivan et al.)				
CIX-203	75.	00/53722	09/14/00	WO (O'Hare and Normand)				
CXLII- 2857 /DB/	76.	04/013280	02/12/04	WO (Davidson et al.)				

OTHER DOCUMENTS - Including Author, Title, Date, Pertinent Pages, Etc.

Examiner Initial	No.	
/DB/ *	77.	Bass, "The short answer," <i>Nature</i> 411:428-429 (2001)
	* 78.	Beigelman et al., "Synthesis of 2'-modified nucleotides and their incorporation into hammerhead ribozymes," <i>Nucleic Acids Research</i> 23(21):4434-4442 (1995)
	* 79.	Bellon et al., "Amino-Linked Ribozymes: Post-Synthetic Conjugation of Half-Ribozymes," <i>Nucleosides & Nucleotides</i> 16:951-954 (1997)
	* 80.	Bellon et al., "Post-synthetically Ligated Ribozymes: An Alternative Approach to Iterative Solid Phase Synthesis," <i>Bioconjugate Chem.</i> 8:204-212 (1997)
	* 81.	Breaker et al., "A DNA enzyme with Mg ²⁺ -dependent RNA phosphoesterase activity," <i>Chemistry & Biology</i> 2(10):655-660 (1995)
	* 82.	Breaker, "Are engineered proteins getting competition from RNA?" <i>Current Opinion in Biotechnology</i> 7:442-448 (1996)
↓	* 83.	Breaker, "Catalytic DNA: in training and seeking employment," <i>Nature Biotechnology</i> 17:422-423 (1999)
/DB/ *	84.	Brennan et al., "Two-Dimensional Parallel Array Technology as a New Approach to

Examiner /David Blanchard/	Date Considered 07/03/2007
----------------------------	----------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with any communication.

Form PTO-1449 U.S. Department of Commerce
Patent and Trademark Office

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Atty. Docket No.

02-030-A

Serial No.

10/366,191

Applicant : Radka et al.

Filing Date:
February 12, 2003Group: Not yet
assigned

/DB/		Automated Combinatorial Solid-Phase Organic Synthesis," <i>Biotechnology and Bioengineering (Combinatorial Chemistry)</i> 61:33-45 (1998)
	* 85.	Brody and Gold, "Aptamers as therapeutic and diagnostic agents," <i>Reviews in Molecular Biotechnology</i> 74:5-13 (2000)
	* 86.	Burgin et al., "Chemically Modified Hammerhead Ribozymes with Improved Catalytic Rates," <i>Biochemistry</i> 35:14090-14097 (1996) (volume no. mistakenly listed as 6)
	* 87.	Caruthers et al., "Chemical Synthesis of Deoxyoligonucleotides and Deoxyoligonucleotide Analogs," <i>Methods in Enzymology</i> 211:3-19 (1992)
	* 88.	Cech, "Ribozymes and Their Medical Implications," <i>JAMA</i> 260:3030-3034 (1988)
	* 89.	Chartrand et al., "An oligodeoxyribonucleotide that supports catalytic activity in the hammerhead ribozyme domain," <i>Nucleic Acids Research</i> 23(20):4092-4096 (1995)
	* 90.	Crooke et al., "Antisense '97: A roundtable on the state of the idustry," <i>Nature Biotechnology</i> 15:519-524 (1997)
	* 91.	Crooke, "Advances in Understanding the Pharmacological Properties of Antisense Oligonucleotides," <i>Advances in Pharmacology</i> 40:1-49 (1997)
	* 92.	Crooke, "Antisense Therapeutics," <i>Biotechnology and Genetic Engineering Reviews</i> 15:121-157 (1998)
	* 93.	Crooke, "Progress in Antisense Technology: The End of the Beginning," <i>Methods in Enzymology</i> 313:3-45 (1999)
	* 94.	Delihias et al., "Natural antisense RNA/target RNA interactions: Possible models for antisense oligonucleotide drug design," <i>Nature Biotechnology</i> 15:751-753 (1997)
	* 95.	Duval-Valentin, "Specific inhibition of transcription by triple helix-forming oligonucleotides," <i>Proc. Natl. Acad. Sci. USA</i> 89:504-508 (1992)
	* 96.	Egholm et al., "PNA hybridizes to complementary oligonucleotides obeying the Watson-Crick hydrogen-bonding rules," <i>Nature</i> 365:566-568 (1993)
	* 97.	Elbashir et al., "Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells," <i>Nature</i> 411:494-498 (2001)
	* 98.	Fox, "Targeting DNA with Triplexes," <i>Current Medicinal Chemistry</i> 7:17-37 (2000)
	* 99.	Freier et al., "Improved free-energy parameters for predictions of RNA duplex stability," <i>Proc. Natl. Acad. Sci. USA</i> 83:9373-9377 (1986) [sometimes referred to as Frier]
	* 100.	Gold et al., "Diversity of Oligonucleotide Functions," <i>Annu. Rev. Biochem.</i> 64:763-797 (1995)
↓ /DB/	* 101.	Halloran and Parker, "The Preparation of Nucleotide-Protein Conjugates: Carbodiimides as Coupling Agents," <i>Journal of Immunology</i> 96:373-378 (1966)

Examiner /David Blanchard/

Date Considered 07/03/2007

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with any communication.

Form PTO-1449 U.S. Department of Commerce
Patent and Trademark Office

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Atty. Docket No.

02-030-A

Serial No.

10/366,191

Applicant : Radka et al.

Filing Date:
February 12, 2003Group: Not yet
assigned


/DB/ ↓	*	102.	Hammann et al., "Length Variation of Helix III in a Hammerhead Ribozyme and Its Influence on Cleavage Activity," <i>Antisense & Nucleic Acid Drug Development</i> 9:25-31 (1999)
	*	103.	Hermann and Patel, "Adaptive Recognition by Nucleic Acid Aptamers," <i>Science</i> 287:820-825 (2000)
	*	104.	Hertel et al., "Numbering System for the Hammerhead," <i>Nucleic Acids Research</i> 20:3252 (1992)
	*	105.	Ishiwata et al., "Physical-Chemistry Characteristics and Biodistribution of Poly(ethylene glycol)-Coated Liposomes Using Poly(oxyethylene) Cholesteryl Ether," <i>Chem. Pharm. Bull.</i> 43:1005-1011 (1995) (mistakenly referred to as Ishiwataet)
	*	106.	Jayasena, "Aptamers: An Emerging Class of Molecules that Rival Antibodies in Diagnostics," <i>Clinical Chemistry</i> 45:1628-1650 (1999)
	*	107.	Kearney et al., "A New Mouse Myeloma Cell Line That Has Lost Immunoglobulin Expression but Permits the Construction of Antibody-Secreting Hybrid Cell Lines," <i>Journal of Immunology</i> 123:1548-1550 (1979)
	*	108.	Kore, et al., "Sequence specificity of the hammerhead ribozyme revisited; the NIH rule," <i>Nucleic Acids Research</i> , 26(18):4116-4120 (1998).
	*	109.	Kusser, "Chemically modified nucleic acid aptamers for in vitro selections: evolving evolution," <i>Reviews in Molecular Biotechnology</i> 74:27-38 (2000)
	*	110.	Lasic and Needham "The 'Stealth' Liposome: A Prototypical Biomaterial," <i>Chemical Reviews</i> 95:2601-2627 (1995)
	*	111.	Lasic and Papahadjopoulos, "Liposomes Revisited," <i>Science</i> 267:1275-1276 (1995)
	*	112.	Limbach et al., "Summary: the modified nucleosides of RNA," <i>Nucleic Acids Research</i> 22(12):2183-2196 (1994)
	*	113.	Liu et al., "Cationic Liposome-mediated Intravenous Gene Delivery," <i>J. Biol. Chem.</i> 270(42):24864-24870 (1995)
	*	114.	Moore and Sharp, "Site-Specific Modification of Pre-mRNA: The 2'-Hydroxyl Groups at the Splice Sites," <i>Science</i> 256:992-996 (1992)
	*	115.	Oku et al., "Real-time analysis of liposomal trafficking in tumor-bearing mice by use of positron emission tomography," <i>Biochimica et Biophysica Acta</i> 1238:86-90 (1995)
	*	116.	Player and Torrence, "The 2-5A System: Modulation of Viral and Cellular Processes Through Acceleration of RNA Degradation," <i>Pharmacol Ther.</i> 78:55-113 (1998)

Examiner /David Blanchard/

Date Considered 07/03/2007

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with any communication.

Form PTO-1449 U.S. Department of Commerce Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Atty. Docket No.	Serial No.
	02-030-A	10/366,191
	Applicant : Radka et al.	
	Filing Date: February 12, 2003	Group: Not yet assigned

/DB/	*	117.	Praseuth et al., "Triple helix formation and the antigene for sequence-specific control of gene expression," <i>Biochimica et Biophysica Acta</i> 1489:181-206 (1999)
	*	118.	Santoro and Joyce, "A general purpose RNA-cleaving DNA enzyme," <i>Proc. Natl. Acad. Sci. USA</i> 94:4262-4266 (1997)
	*	119.	Santoro et al., "RNA Cleavage by a DNA Enzyme with Extended Chemical Functionality," <i>J. Am. Chem. Soc.</i> 122:2433-2439 (2000)
	*	120.	Scaringe et al., "Chemical synthesis of biologically active oligoribonucleotides using β -cyanoethyl protected ribonucleoside phosphoramidites," <i>Nucl. Acids Res.</i> 18:5433-5441 (1990)
	*	121.	Schmajuk et al., "Antisense Oligonucleotides with Different Backbones," <i>The Journal of Biological Chemistry</i> 274:21783-21789 (1999)
	*	122.	Shabarova et al., "Chemical ligation of DNA: The first non-enzymatic assembly of a biologically active gene," <i>Nucleic Acids Research</i> 19:4247-4251 (1991)
	*	123.	Silverman et al., "Selective RNA Cleavage by Isolated RNase L Activated with 2-5A Antisense Chimeric Oligonucleotides," <i>Methods in Enzymology</i> 313:522-533 (1999)
	*	124.	Stein and Cheng, "Antisense Oligonucleotides as Therapeutic Agents - Is the Bullet Really Magical?" <i>Science</i> 261:1004-1288 (1993)
	*	125.	Stein et al., "A Specificity Comparison of Four Antisense Types: Morpholino, 2'-O-Methyl RNA, DNA, and Phosphorothioate DNA," <i>Antisense & Nucleic Acid Drug Development</i> 7:151-157 (1997)
	*	126.	Sullenger et al., "Overexpression of TAR Sequences Renders Cells Resistant to Human Immunodeficiency Virus Replication," <i>Cell</i> 63:601-608 (1990)
	*	127.	Sun, "Technology evaluation: SELEX, Giliad Sciences Inc," <i>Current Opinion in Molecular Therapeutics</i> 2:100-105 (2000)
	*	128.	Torrence et al., "Targeting RNA for degradation with a (2'-5') oligoadenylate-antisense chimera," <i>Proc. Natl. Acad. Sci. USA</i> 90:1300-1304 (1993)
	*	129.	Turner et al., "Improved Parameters for Prediction of RNA Structure," <i>Cold Spring Harbor Symposia on Quantitative Biology</i> Volume LII, pp. 123-133 (1987)
	*	130.	Turner et al., "Free Energy Increments for Hydrogen Bonds in Nucleic Acid Base Pairs," <i>J. Am. Chem. Soc.</i> 109:3783-3785 (1987)
	*	131.	Usman and Cedergren, "Exploiting the chemical synthesis of RNA," <i>TIBS</i> 17:334-339 (1992)
 /DB/	*	132.	Usman et al., "Automated Chemical Synthesis of Long Oligoribonucleotides Using 2'-O-Silylated Ribonucleoside 3'-O-Phosphoramidites on a Controlled-Pore Glass Support: Synthesis of a 43-Nucleotide Sequence Similar to the 3'-Half Molecule of an <i>Escherichia coli</i> Formylmethionine tRNA," <i>J. Am. Chem. Soc.</i> 109:7845-7854

Examiner /David Blanchard/	Date Considered 07/03/2007
----------------------------	----------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with any communication.

Form PTO-1449 U.S. Department of Commerce Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Atty. Docket No. 02-030-A	Serial No. 10/366,191
	Applicant : Radka et al.	
	Filing Date: February 12, 2003	Group: Not yet assigned

		(1987)
/DB/	*	133. Usman et al., "Chemical modification of hammerhead ribozymes: activity and nuclease resistance," <u>Nucleic Acids Symposium Series 31:163-164 (1994)</u>
	*	134. Usman et al., "Hammerhead ribozyme engineering," <u>Current Opinion in Structural Biology 1:527-533(1996)</u>
	*	135. Werner and Uhlenbeck, "The effect of base mismatches in the substrate recognition helices of hammerhead ribozymes on binding and catalysis," <u>Nucleic Acids Research 23:2092-2096 (1995)</u>
	*	136. Wincott et al., "Synthesis, deprotection, analysis and purification of RNA and ribozymes," <u>Nucleic Acids Research 23(14):2677-2684 (1995)</u>
	*	137. Wincott et al., "Synthesis, deprotection, analysis and purification of RNA and ribozymes," <u>Nucleic Acids Research 23(14):2677-2684 (1995)</u>
	*	138. Wincott et al., "A Practical Method for the Production of RNA and Ribozymes," <u>Methods in Molecular Biology 74:59-69 (1997)</u>
	*	139. Yoshikawa et al., "Studies of Phosphorylation. III. Selective Phosphorylation of Unprotected Nucleosides," <u>Bulletin of the Chemical Society of Japan 42:3505-3508 (1969)</u>
CXL -2778		140. Bahramian et al., "Transcriptional and Posttranscriptional Silencing of Rodent $\alpha 1(I)$ Collagen by a Homologous Transcriptionally Self-Silenced Transgene," <u>Molecular and Cellular Biology, 274-283 (1999)</u>
CXXI-2320		141. Fire et al., "Potent and Specific Genetic Interference by Double-Stranded RNA in <i>Caenorhabditis Elegans</i> ," <u>Nature 391:806-811(1998)</u>
CXL -2779		142. Hamilton, et al., "A Species of Small Antisense RNA in Posttranscriptional Gene Silencing in Plants," <u>Science, 286, 950-952 (1999)</u>
CXLI -2824		143. Lin et al., "Policing rogue genes," <u>Nature, 402, 128-129 (1999)</u>
CXLI -2826		144. Sharp et al., "RNAi and double-strand RNA," <u>Genes & Development, 13:139-141 (1999)</u>
CXLI -2828		145. Strauss, Evelyn, "Molecular Biology: Candidate 'Gene Silencers' Found," <u>Molecular Biology, Vol. 286, No. 5441, p. 886 (1999) [sometimes mistakenly referred to as being published in Science]</u>
CXXIV-2395		146. Tuschl et al., "Targeted mRNA Degradation by Double-Stranded RNA In Vitro," <u>Genes & Development 13:3191-3197 (1999)</u>
CXLI -2827		147. Waterhouse et al., "Virus resistance and gene silencing in plants can be induced by simultaneous expression of sense and antisense RNA," <u>Proc. Natl. Acad. Sci. USA, 95, 13959-13964 (1998)</u>
IX-193		148. Durand et al., "Circular Dichroism Studies of an Oligodeoxyribonucleotide Containing a Hairpin Loop Made of a Hexaethylene Glycol Chain: Conformation and Stability," <u>Nucleic Acids Research 18:6353-6359 (1990) [sometimes referred to as Seela and Kaiser]</u>
XIII-266 /DB/		149. Seela and Kaiser, "Oligodeoxyribonucleotides containing 1,3-propanediol as nucleoside substitute," <u>Nucleic Acids Research 15:3113-3129 (1987)</u>

Examiner /David Blanchard/	Date Considered 07/03/2007
----------------------------	----------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with any communication.

Form PTO-1449 U.S. Department of Commerce Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Atty. Docket No.	Serial No.
	02-030-A	10/366,191
	Applicant : Radka et al.	
	Filing Date: February 12, 2003	Group: Not yet assigned

/DB/	IX-186	150.	Cload and Schepartz, "Polyether Tethered Oligonucleotide Probes," <u>J. Am. Chem. Soc.</u> 113:6324-6326 (1991)
	IX-185	151.	Richardson and Schepartz, "Tethered Oligonucleotide Probes. A Strategy for the Recognition of Structured RNA," <u>J. Am. Chem. Soc.</u> 113:5109-5111 (1991)
	IX-196	152.	Ma et al., "Design and Synthesis of RNA Miniduplexes via a Synthetic Linker Approach. 2. Generation of Covalently Closed, Double-Stranded Cyclic HIV-1 TAR RNA Analogs with High Tat-Binding Affinity," <u>Nucleic Acids Research</u> 21:2585-2589 (1993)
	IX-195	153.	Ma et al., "Design and Synthesis of RNA Miniduplexes via a Synthetic Linker Approach," <u>Biochemistry</u> 32:1751-1758 (1993)
	IX-189	154.	McCurdy et al., "Deoxyoligonucleotides with Inverted Polarity: Synthesis and Use in Triple-Helix Formation" <u>Nucleosides & Nucleotides</u> 10:287-290 (1991)
	IX-188	155.	Jaschke et al., "Automated Incorporation of Polyethylene Glycol into Synthetic Oligonucleotides," <u>Tetrahedron Letters</u> 34:301-304 (1993) (sometimes mistakenly referred to as Jsckke)
	IX-184	156.	Ono et al., "DNA Triplex Formation of Oligonucleotide Analogues Consisting of Linker Groups and Octamer Segments That Have Opposite Sugar-Phosphate Backbone Polarities," <u>Biochemistry</u> 30:9914-9921 (1991)
	IX-183	157.	Ferentz and Verdine, "Disulfied Cross-Linked Oligonucleotides," <u>J. Am. Chem. Soc.</u> 113:4000-4002 (1991)
	CXLII-2855	158.	Schwarz et al., "Asymmetry in the Assembly of the RNAi Enzyme Complex," <u>Cell</u> , 1115, 199-208 (2003)
	CXXIV-2394	159.	Zamore et al., "RNAi: Double-Stranded RNA Directs the ATP-Dependent Cleavage of mRNA at 21 to 23 Nucleotide Intervals," <u>Cell</u> 101:25-33 (2000)
	CXXXVII-2731	160.	Allshire, "RNAi and Heterochromatin - A Hushed-up Affair," <u>Science</u> 297:1818-1819 (2002)
	CXXXVII-2726	161.	Volpe et al., "Regulation of Heterochromatic Silencing and Histone H3 Lysine-9 Methylation by RNAi," <u>Science</u> 297:1833-1837 (2002)
	CXXXVII-2732	162.	Hall et al., "Establishment and Maintenance of a Heterochromatin Domain," <u>Science</u> 297:2232-2237 (2002)
	CXXXVII-2730	163.	Hutvagner and Zamore, "A MicroRNA in a Multiple-Turnover RNAi Enzyme Complex," <u>Science</u> 297:2056-2060 (2002)
	CXXXVII-2728	164.	McManus et al., "Gene Silencing Using Micro-RNA Designed Hairpins," <u>RNA</u> 8:842-850 (2002)
	CXXXVII-2727	165.	Reinhart et al., "MicroRNAs in Plants," <u>Genes & Development</u> 16:1616-1626 (2002)
✓	CXXXVII-2724	166.	Reinhart and Bartel, "Small RNAs Correspond to Centromer Heterochromatic Repeats," <u>Science</u> 297:1831 (2002)
/DB/	CXXXV-2682	167.	Martinez et al., "Single-Stranded Antisense siRNAs Guide Target RNA Cleavage in RNAi," <u>Cell</u> 110:563-574 (2002)

Examiner /David Blanchard/	Date Considered 07/03/2007
----------------------------	----------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with any communication.

Form PTO-1449 U.S. Department of Commerce Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Atty. Docket No.	Serial No.
	02-030-A	10/366,191
	Applicant : Radka et al.	
	Filing Date: February 12, 2003	Group: Not yet assigned

/DB/	CXXXVI-2706	168.	Schwarz et al., "Evidence that siRNAs Function as Guides, Not Primers, in the <i>Drosophila</i> and Human RNAi Pathways," <i>Molecular Cell</i> 10:537-548 (2002)
	CXLII-2853	169.	Verdel et al., "RNAi-Mediated Targeting of Heterochromatin by the RITS Complex, <i>Science</i> , 303, 672-676 (2004)
	CXXXVII-2729	170.	Jenuwein, "An RNA-Guided Pathway for the Epigenome," <i>Science</i> 297:2215-2218 (2002)
	XXXXIX-3	171.	Akhtar and Juliano, "Cellular Uptake and Intracellular Fate of AntiSense Oligonucleotides," <i>Trends Cell Biol.</i> 2:139-144 (1992)
	LXVIII-765	172.	Elkins and Rossi, "Ch. 2 - Cellular Delivery of Ribozymes," in <i>Delivery Strategies for Antisense Oligonucleotide Therapeutics</i> , edited by Akhtar, CRC Press, pp. 17-220 (1995)
	CII-1840	173.	Maurer et al., "Lipid-based systems for the intracellular delivery of genetic drugs," <i>Molecular Membrane Biology</i> 16:129-140 (1999)
	CII-1829	174.	Hofland and Huang, "Formulation and Delivery of Nucleic Acids," <i>Handbook of Exp. Pharmacol.</i> 137:165-192 (1999)
	CII-1832	175.	Lee and Larson, "Modified Liposome Formulations for Cytosolic Delivery of Macromolecules," <i>ACS Symposium Series</i> 752:184-192 (2000)
	CXXXVIII-2755	176.	Gonzalez et al., "New Class of Polymers for the Delivery of Macromolecular Therapeutics," <i>Bioconjugate Chem.</i> 10:1068-1074 (1999)
	CXII-2097	177.	Sommer et al., "The Spread and Uptake Pattern of Intracerebrally Administered Oligonucleotides in Nerve and Glial Cell Populations of the Rat Brain," <i>Antisense & Nucleic Acid Drug Development</i> 8:75-85 (1998)
	CXLIV-2870	178.	Epa et al., "Downregulation of the p75 Neurotrophin Receptor in Tissue Culture and In Vivo, Using β -Cyclodextrin-Adamantane-Oligonucleotide Conjugates," <i>Antisense & Nucleic Acid Drug Development</i> , 10:469-478 (2000)
	CXXVI-2419	179.	Broadbent et al., "Distribution and stability of antisense phosphorothioate oligonucleotides in rodent brain following direct intraparenchymal controlled-rate infusion," <i>J Neurosurg</i> 88:734-742 (1998)
	CXI-2076	180.	Karle et al., "Differential Changes in Induced Seizures After Hippocampal Treatment of Rats with an Antisense Oligodeoxynucleotide to the GABA _A Receptor γ 2 Subunit," <i>Euro. Jour. of Pharmacology</i> 340:153-160 (1997)
	CXI-2077	181.	Bannai et al., "Effect of Injection of Antisense of Oligodeoxynucleotides of GAD Isozymes into Rat Ventromedial Hypothalamus on Food Intake and Locomotor Activity," <i>Brain Research</i> 784:305-315 (1998)
	CXI-2084	182.	Rajakumar et al., "Effects of Intrastriatal Infusion of D ₂ Receptor Antisense Oligonucleotide on Apomorphine-Induced Behaviors in the Rat," <i>Synapse</i> 26:199-208 (1997)
	CXVIII-2249	183.	Wu-Pong et al., "Antisense c-myc Oligonucleotide Cellular Uptake and Activity," <i>Antisense Research and Development</i> 4:155-163 (1994)
	CXI-2078	184.	Bannai et al., "Water-absorbent Polymer as a Carrier for a Discrete Deposit of Antisense Oligodeoxynucleotides in the Central Nervous System," <i>Brain Research Protocols</i> 3:83-87 (1998)
	CXII-2095	185.	Simantov et al., "Dopamine-Induced Apoptosis in Human Neuronal Cells: Inhibition by Nucleic Acids Antisense to the Dopamine Transporter," <i>Neuroscience</i> 74(1):39-50 (1996)
	XCVI-1665	186.	Emerich et al., "Biocompatibility of Poly (DL-Lactide-co-Glycolide) Microspheres Implanted Into the Brain," <i>Cell Transplantation</i> 8:47-58 (1999)
/DB/	XCVI-1653	187.	Boado et al., "Drug Delivery of Antisense Molecules to the Brain for Treatment of Alzheimer's Disease and Cerebral AIDS," <i>Journal of Pharmaceutical Sciences</i> 87:1308-1315 (1998)

Examiner	/David Blanchard/	Date Considered	07/03/2007
----------	-------------------	-----------------	------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with any communication.

Form PTO-1449 U.S. Department of Commerce Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Atty. Docket No. 02-030-A	Serial No. 10/366,191
	Applicant : Radka et al.	
	Filing Date: February 12, 2003	Group: Not yet assigned

/DB/	XCV-1599	188.	Tyler et al., "Specific gene blockade shows that peptide nucleic acids readily enter neuronal cells in vivo," <i>FEBS Letters</i> 421:280-284 (1998)
	XCVI-1622	189.	Pardridge et al., "Vector-mediated delivery of a polyamide ("peptide") nucleic acid analogue through the blood-brain barrier <i>in vivo</i> ," <i>Proc. Natl. Acad. Sci. USA</i> 92:5592-5596 (1995)
	XCVI-1667	190.	Boado, "Antisense drug delivery through the blood-brain barrier," <i>Advanced Drug Delivery Reviews</i> 15:73-107 (1995)
	CV-1936	191.	Aldrian-Herrada et al., "A peptide nucleic acid (PNA) is more rapidly internalized in cultured neurons when coupled to a <i>retro-inverso</i> delivery peptide. The antisense activity depresses the target mRNA and protein in magnocellular oxytocin neurons," <i>Nucleic Acids Research</i> 26:4910-4916 (1998)
	XCV-1600	192.	Tyler et al., "Peptide nucleic acids targeted to the neurotensin receptor and administered i.p. cross the blood-brain barrier and specifically reduce gene expression," <i>Proc. Natl. Acad. Sci. USA</i> 96:7053-7058 (1999)
	CXXIII-2368	193.	Wu and Wu, "Receptor-mediated <i>in Vitro</i> Gene Transformation by a Soluble DNA Carrier System," <i>The Journ. of Biol. Chem.</i> 262:4429-4432 (1987)
	CXXVI-2408	194.	Baenziger and Fiete, "Galactose and N-Acetylgalactosamine-Specific Endocytosis of Glycopeptides by Isolated Rat Hepatocytes," <i>Cell</i> 22:611-620 (1980)
	CXXIII-2369	195.	Connolly et al., "Binding and Endocytosis of Cluster Glycosides by Rabbit Hepatocytes," <i>The Journ. of Biol. Chem.</i> 257:939-945 (1982)
	CXXVI-2413	196.	Lee and Lee, "Preparation of Cluster Glycosides of N-Acetylgalactosamine That Have Subnanomolar Binding Constants Towards the Mammalian Hepatic Gal/GalNAc-specific Receptor," <i>Glyconjugates J.</i> 4:317-328 (1987)
	CXXVI-2409	197.	Ponpipom et al., "Cell-Specific Ligands for Selective Drug Delivery to Tissues and Organs," <i>J. Med. Chem.</i> 24:1388-1395 (1981)
	CXLI-2809	198.	Yamada et al., "Nanoparticles for the delivery of genes and drugs to human hepatocytes," <i>Nature Biology</i> , Published online: 29 June 2003, doi:10.1038/nbt843 (August 2003 Volume 21 Number 8 pp 885-890) (2003) [mistakenly referred to as Yamado]
/DB/	CXLII-2856	199.	Pal-Bhadra et al., "Heterochromatic Silencing and HP1 Localizatin in Drosophila Are Dependent on the RNAi Machinery," <i>Science</i> , 303, 669-672 (2004)

Examiner /David Blanchard/	Date Considered 07/03/2007
----------------------------	----------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with any communication.

Form PTO-1449 U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

Serial No.

02-030-A

10/366,191

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Applicant : Radka et al.

Filing Date:
February 12, 2003Group: Not yet
assigned**U.S. PATENT APPLICATION DOCUMENTS**

Examiner Initial	No.	Document Number	Filing Date	Name	Publication Date if Appropriate
/DB/	1.	10/720448	11/24/03	McSwiggen et al.	
/DB/	2.	2002-0130430		Castor	09/19/02

U.S. PATENT DOCUMENTS

Examiner Initial	No.	Document Number	Date	Name	Class	Subclass	Filing Date
/DB/	3.	6,140,491	10/31/00	Usman			

FOREIGN PATENT DOCUMENTS

Examiner Initial	No.	Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
/DB/	4.	03/070918	08/28/03	WO (McSwiggen et al)				
/DB/	5.	03/047518	06/12/03	WO (Wang et al)				
/DB/	6.	03/046185	06/05/03	WO (Wang)				

Examiner /David Blanchard/

Date Considered 07/03/2007

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with any communication.